Colchicine: Colchicine 0.5mg tablets once a day for 3 to 4.5 years
Placebo: Placebo tablets once a day for 3 to 4.5 years
Study summary
The goal of this clinical trial is to evaluate the effect of treatment with colchicine 0.5mg once daily as compared to placebo in patients with knee or hip osteoarthritis on the incidence of first occurrence of knee or hip replacement. The main question it aims to answer is:
Does colchicine lower the number of knee or hip replacements in participants with osteoarthritis?
Researchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine works to treat osteoarthritis.
Participants will:
* take colchicine every day for 3 tot 4.5 years
* visit the clinic every year for check-up and tests such as blood samples and x-rays
* fill in questionnaires every 3 months
Eligibility
Sex
ALL
Min age
45 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* clinical diagnosis of knee or hip OA
* 45 ≤ age ≤ 80 (upper age limit is similar to that in the LoDoCo2 trial and takes in consideration the lower number of joint replacements in people older than 80 years)
* documented radiographic changes typical for advanced knee/hip OA (Kellgren \& Lawrence score ≥ 2), or at least 2-year history of complaints due to OA in the hip and/or knee
Exclusion Criteria:
* On a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause
* Any absolute contraindication for knee or hip replacement in the future
* More than one previous hip or knee replacements
* Other known medical disease that may affect joints
* Known generalized pain syndromes such as fibromyalgia
* Renal impairment as evidenced by serum creatinine \>150µmol/l or estimated glomerular filtration rate (eGFR) \<50mL/min/1.73m2
* Liver function impairment as evidenced by serum alanine transferase (ALAT) \> 3 ULN (upper limit of normal)
* Blood dyscrasia
* High frailty (clinical frailty scale ≥ 7) or predicted life expectancy \< 5 years
* Peripheral neuritis, myositis or marked myo-sensitivity to statins
* Current use of colchicine for another indication
* Intolerance to colchicine
* use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors \& anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine)
* Current enrollment in another trial
* Incapacitated patients
* Pregnant or breastfeeding female
* Fertile female participants not taking sufficient anti-conception
* Male participants unwilling to use effective contraception during the study to prevent pregnancy
Primary outcome measure(s)
Time to first knee or hip replacement — From randomization until the date of first documented knee or hip replacement, date of death, date of lost to follow-up, or study end-date, whichever comes first, assessed up to 4.5 years
Trial sites (1)
Facility
City
Region
Status
Sint Maartenskliniek
Nijmegen
Netherlands
Recruiting
More Sint Maartenskliniek trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.